Deans' stroke musings: Statin myopathy: Over-rated and under-treated

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, June 13, 2016

Statin myopathy: Over-rated and under-treated

You'll have to demand your doctor figure out your myopathy.
http://www.mdlinx.com/internal-medicine/medical-news-article/2016/06/13/statin/6704352/?

Current Opinion in Cardiology, 06/13/2016Maghsoodi N, et al.

The purpose of this study is to conclude the definition of statin–related muscle disorders, causative factors, and recommended management strategies. Statin–related muscle adverse–effects are common. Secondary causes of muscle disease unmasked by statin therapy should be identified. Most patients can be managed by adjustment of standard treatment protocols.

A number of consensus groups have defined and classified statin–related muscle disorders, whereas others have suggested diagnostic and management strategies. Mechanisms behind statin–related muscle toxicity have been identified.
Therapeutic and clinical investigation pathways have been reviewed and algorithms defined.
Novel drugs have become available to reduce low–density lipoprotein cholesterol levels that are not associated with causing muscle side–effects.

Go to PubMed Go to Abstract Print Article Summary Cat 2 CME Report